deltatrials

Clinical Trial Intelligence

Track how clinical trials change over time. 600,000+ trials with full version history, status transitions, and cross-links.

Browse Directory

Browse by Condition

View all conditions →
Healthy
9,670 trials
Breast cancer
7,747 trials
Obesity
6,548 trials
Stroke
4,622 trials
Depression
4,021 trials
Prostate cancer
3,965 trials
Pain
3,914 trials
Hypertension
3,772 trials

Browse by Location

View all locations →
New York, United States
24,782 trials
Houston, United States
21,386 trials
Boston, United States
20,179 trials
Chicago, United States
16,778 trials
Philadelphia, United States
16,362 trials
Los Angeles, United States
15,952 trials
Beijing, China
14,538 trials
Paris, France
13,924 trials

Recently Updated Trials

NCT ID Title Status Last Update
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced ... ACTIVE_NOT_RECRUITING 2026-04-30
NCT01272037 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemoth... ACTIVE_NOT_RECRUITING 2026-04-30
NCT02194738 Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Can... ACTIVE_NOT_RECRUITING 2026-04-30
NCT02193282 Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell L... ACTIVE_NOT_RECRUITING 2026-04-30
NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors ACTIVE_NOT_RECRUITING 2026-04-30
NCT03793179 Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Tre... ACTIVE_NOT_RECRUITING 2026-04-30
NCT04267848 Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemoth... RECRUITING 2026-04-30
NCT04387656 NCI COVID-19 in Cancer Patients, NCCAPS Study ACTIVE_NOT_RECRUITING 2026-04-30
NCT02954874 Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative... ACTIVE_NOT_RECRUITING 2026-04-30
NCT01886872 Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib ... ACTIVE_NOT_RECRUITING 2026-04-30
NCT03233711 Nivolumab After Combined Modality Therapy in Treating Patients With High Risk St... ACTIVE_NOT_RECRUITING 2026-04-30
NCT03907488 Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy i... ACTIVE_NOT_RECRUITING 2026-04-30
NCT02595944 Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA... ACTIVE_NOT_RECRUITING 2026-04-30
NCT03244384 Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Blad... ACTIVE_NOT_RECRUITING 2026-04-30
NCT00588770 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or ... ACTIVE_NOT_RECRUITING 2026-04-30
NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety i... ACTIVE_NOT_RECRUITING 2026-04-30
NCT03701282 Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Li... ACTIVE_NOT_RECRUITING 2026-04-30
NCT03660826 Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Ol... ACTIVE_NOT_RECRUITING 2026-04-30
NCT02048813 Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, a... ACTIVE_NOT_RECRUITING 2026-04-30
NCT03793166 Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab W... ACTIVE_NOT_RECRUITING 2026-04-30